The global market for Oncolytic Virus Immunotherapy was valued at US$156.8 Million in 2024 and is projected to reach US$429.1 Million by 2030, growing at a CAGR of 18.3% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Oncolytic Virus Immunotherapy market.
Despite early setbacks in the 1990s, recent advances in molecular virology, gene editing, and immune-oncology have revitalized interest in this approach. The 2015 approval of T-VEC (talimogene laherparepvec) by the FDA for melanoma marked a watershed moment, validating the concept of oncolytic virus therapy in clinical practice. Since then, a surge of clinical trials targeting multiple cancer types - including glioblastoma, colorectal cancer, pancreatic cancer, and non-small cell lung cancer - has expanded the scope and credibility of the modality. As monotherapies and in combination with checkpoint inhibitors, oncolytic viruses are becoming a cornerstone of next-generation immunotherapy regimens.
Combination therapies are a major focus, with oncolytic viruses increasingly paired with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1), CAR-T therapies, or radiotherapy to overcome resistance mechanisms and enhance systemic anti-tumor responses. Intratumoral delivery methods, dose escalation protocols, and multi-site administration strategies are improving virus biodistribution and reducing off-target effects. Liquid biopsy and imaging biomarkers are being developed to monitor viral persistence, immune infiltration, and treatment response in real time. These advancements are transitioning oncolytic virotherapy from a niche modality into an integral component of multi-modal cancer treatment frameworks.
North America leads clinical development, with the U.S. hosting the majority of early-phase and pivotal trials. The presence of major virotherapy developers, robust funding ecosystems, and an innovation-friendly regulatory environment accelerates translational progress. Europe follows with strong academic-industry partnerships and regulatory support through the EMA’s Advanced Therapy Medicinal Product (ATMP) designation. Asia-Pacific is emerging as a competitive landscape, particularly in China, where biotech firms are investing heavily in oncolytic platforms and regulatory reforms are enabling faster trial initiation. Global oncology centers are increasingly integrating oncolytic viruses into compassionate use programs and combination trial protocols.
Pharmaceutical companies are accelerating R&D through collaborations with academic virologists, biotech firms, and clinical oncology networks. AI-driven viral vector design, CRISPR-enabled transgene integration, and intratumoral microdosing techniques are improving specificity and safety profiles. Investment in scalable manufacturing, lyophilized formulations, and cold-chain logistics is supporting broader market readiness. As personalized cancer vaccines and immune cell therapies gain traction, oncolytic viruses are poised to serve as immune amplifiers that bridge innate and adaptive response layers. The future of cancer immunotherapy will be increasingly shaped by these programmable, self-amplifying, and immune-sensitizing viral agents.
Segments: Type (Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus, Other Types); Administration Route (Intratumoral Route, Intravenous Route); Application (Melanoma Application, Non-small Cell Lung Cancer Application, Pancreatic Cancer Application, Breast Cancer Application, Other Applications).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
Global Oncolytic Virus Immunotherapy Market - Key Trends & Drivers Summarized
Why Are Oncolytic Viruses Re-emerging as a Disruptive Modality in Cancer Immunotherapy?
Oncolytic virus immunotherapy is gaining renewed momentum in oncology as a dual-action therapeutic strategy that combines direct tumor lysis with immune system priming. These genetically engineered or naturally occurring viruses selectively infect and replicate in tumor cells, causing their destruction while releasing tumor-associated antigens that stimulate anti-cancer immune responses. Unlike traditional chemotherapy or radiation, oncolytic viruses act locally at the tumor site and systemically through immune activation, positioning them as versatile agents in both solid and hematologic malignancies.Despite early setbacks in the 1990s, recent advances in molecular virology, gene editing, and immune-oncology have revitalized interest in this approach. The 2015 approval of T-VEC (talimogene laherparepvec) by the FDA for melanoma marked a watershed moment, validating the concept of oncolytic virus therapy in clinical practice. Since then, a surge of clinical trials targeting multiple cancer types - including glioblastoma, colorectal cancer, pancreatic cancer, and non-small cell lung cancer - has expanded the scope and credibility of the modality. As monotherapies and in combination with checkpoint inhibitors, oncolytic viruses are becoming a cornerstone of next-generation immunotherapy regimens.
How Are Genetic Engineering and Combination Protocols Expanding the Potential of Oncolytic Virotherapy?
Recent breakthroughs in synthetic biology and vector engineering are significantly enhancing the safety, selectivity, and immune-stimulatory capabilities of oncolytic viruses. New viral constructs - based on herpes simplex virus (HSV), adenovirus, vaccinia virus, and reovirus - are being armed with immune-boosting transgenes such as GM-CSF, interleukins, or checkpoint blockade peptides. These modifications allow the virus to not only destroy tumor cells but also convert the tumor microenvironment (TME) into an immunologically active site.Combination therapies are a major focus, with oncolytic viruses increasingly paired with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1), CAR-T therapies, or radiotherapy to overcome resistance mechanisms and enhance systemic anti-tumor responses. Intratumoral delivery methods, dose escalation protocols, and multi-site administration strategies are improving virus biodistribution and reducing off-target effects. Liquid biopsy and imaging biomarkers are being developed to monitor viral persistence, immune infiltration, and treatment response in real time. These advancements are transitioning oncolytic virotherapy from a niche modality into an integral component of multi-modal cancer treatment frameworks.
Which Tumor Types and Geographies Are Shaping the Clinical and Commercial Landscape for Oncolytic Viruses?
Solid tumors with immunosuppressive microenvironments - such as melanoma, glioblastoma, pancreatic cancer, and hepatocellular carcinoma - are prime candidates for oncolytic virotherapy. These cancers typically respond poorly to conventional therapies and often lack T-cell infiltration, which oncolytic viruses can help overcome. Hematologic malignancies like lymphoma and multiple myeloma are also being targeted through engineered viruses capable of engaging both innate and adaptive immunity.North America leads clinical development, with the U.S. hosting the majority of early-phase and pivotal trials. The presence of major virotherapy developers, robust funding ecosystems, and an innovation-friendly regulatory environment accelerates translational progress. Europe follows with strong academic-industry partnerships and regulatory support through the EMA’s Advanced Therapy Medicinal Product (ATMP) designation. Asia-Pacific is emerging as a competitive landscape, particularly in China, where biotech firms are investing heavily in oncolytic platforms and regulatory reforms are enabling faster trial initiation. Global oncology centers are increasingly integrating oncolytic viruses into compassionate use programs and combination trial protocols.
What Is Powering Long-Term Growth and Scientific Innovation in the Oncolytic Virus Immunotherapy Market?
The growth in the oncolytic virus immunotherapy market is powered by a paradigm shift toward immune-driven cancer control, rising incidence of refractory tumors, and growing regulatory openness to gene-modified biologicals. Oncolytic viruses offer a platform approach with customizable payloads and delivery options, making them highly adaptable to evolving immuno-oncology landscapes. Their ability to initiate cold-to-hot tumor conversion addresses one of the biggest challenges in cancer immunotherapy today.Pharmaceutical companies are accelerating R&D through collaborations with academic virologists, biotech firms, and clinical oncology networks. AI-driven viral vector design, CRISPR-enabled transgene integration, and intratumoral microdosing techniques are improving specificity and safety profiles. Investment in scalable manufacturing, lyophilized formulations, and cold-chain logistics is supporting broader market readiness. As personalized cancer vaccines and immune cell therapies gain traction, oncolytic viruses are poised to serve as immune amplifiers that bridge innate and adaptive response layers. The future of cancer immunotherapy will be increasingly shaped by these programmable, self-amplifying, and immune-sensitizing viral agents.
Report Scope
The report analyzes the Oncolytic Virus Immunotherapy market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.Segments: Type (Herpes Simplex Virus, Vaccinia Virus, Adenovirus, Reovirus, Other Types); Administration Route (Intratumoral Route, Intravenous Route); Application (Melanoma Application, Non-small Cell Lung Cancer Application, Pancreatic Cancer Application, Breast Cancer Application, Other Applications).
Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Key Insights:
- Market Growth: Understand the significant growth trajectory of the Herpes Simplex Virus segment, which is expected to reach US$189.7 Million by 2030 with a CAGR of a 18.6%. The Vaccinia Virus segment is also set to grow at 15.3% CAGR over the analysis period.
- Regional Analysis: Gain insights into the U.S. market, valued at $42.7 Million in 2024, and China, forecasted to grow at an impressive 24.8% CAGR to reach $99.7 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.
Why You Should Buy This Report:
- Detailed Market Analysis: Access a thorough analysis of the Global Oncolytic Virus Immunotherapy Market, covering all major geographic regions and market segments.
- Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
- Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Oncolytic Virus Immunotherapy Market.
- Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.
Key Questions Answered:
- How is the Global Oncolytic Virus Immunotherapy Market expected to evolve by 2030?
- What are the main drivers and restraints affecting the market?
- Which market segments will grow the most over the forecast period?
- How will market shares for different regions and segments change by 2030?
- Who are the leading players in the market, and what are their prospects?
Report Features:
- Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
- In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
- Company Profiles: Coverage of players such as Amgen Inc., CG Oncology, Creative Biolabs, Daiichi Sankyo Co., Ltd., Genelux Corporation and more.
- Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.
Some of the 41 companies featured in this Oncolytic Virus Immunotherapy market report include:
- Amgen Inc.
- CG Oncology
- Creative Biolabs
- Daiichi Sankyo Co., Ltd.
- Genelux Corporation
- ImmVirX
- Imugene Limited
- Lokon Pharma AB
- Merck & Co., Inc.
- Oncolys BioPharma Inc.
- Oncolytics Biotech Inc.
- Oncorus Inc.
- Replimune Group Inc.
- SillaJen, Inc.
- Sorrento Therapeutics, Inc.
- Syneos Health, Inc.
- TILT Biotherapeutics Ltd.
- Transgene S.A.
- Viralytics Ltd.
- ViraTherapeutics GmbH
Tariff Impact Analysis: Key Insights for 2025
Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.
What's Included in This Edition:
- Tariff-adjusted market forecasts by region and segment
- Analysis of cost and supply chain implications by sourcing and trade exposure
- Strategic insights into geographic shifts
Buyers receive a free July 2025 update with:
- Finalized tariff impacts and new trade agreement effects
- Updated projections reflecting global sourcing and cost shifts
- Expanded country-specific coverage across the industry
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISCANADAITALYSPAINRUSSIAREST OF EUROPESOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
AUSTRALIA
INDIA
LATIN AMERICA
MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen Inc.
- CG Oncology
- Creative Biolabs
- Daiichi Sankyo Co., Ltd.
- Genelux Corporation
- ImmVirX
- Imugene Limited
- Lokon Pharma AB
- Merck & Co., Inc.
- Oncolys BioPharma Inc.
- Oncolytics Biotech Inc.
- Oncorus Inc.
- Replimune Group Inc.
- SillaJen, Inc.
- Sorrento Therapeutics, Inc.
- Syneos Health, Inc.
- TILT Biotherapeutics Ltd.
- Transgene S.A.
- Viralytics Ltd.
- ViraTherapeutics GmbH
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 383 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 156.8 Million |
| Forecasted Market Value ( USD | $ 429.1 Million |
| Compound Annual Growth Rate | 18.3% |
| Regions Covered | Global |
